Company news
ALX Oncology Holdings Inc. news in 2022
ALX Oncology Holdings Inc.'s news releases, calls and decks from 2022, newest first.
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia
December 11, 2022
ALX Oncology Appoints Scott Garland to its Board of Directors
November 28, 2022
ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
November 7, 2022
ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting
November 2, 2022
ALX Oncology Announces Upcoming Investor Conference Participation
November 1, 2022
ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept
October 30, 2022
ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 4, 2022
ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
September 20, 2022
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer
August 15, 2022
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer
August 14, 2022
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
August 10, 2022
ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
August 7, 2022
ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma
July 31, 2022
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia
June 28, 2022
ALX Oncology Announces Evorpacept Clinical Program Updates
June 2, 2022
ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
May 8, 2022
ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors
April 11, 2022
ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer
March 1, 2022
ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones
February 27, 2022
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer
January 26, 2022
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
January 9, 2022